RapidFACT reduces time-consuming drug optimisation process
Quotient Clinical, a division of drug development services provider Quotient Bioresearch, has published a white paper demonstrating the capabilities of its RapidFACT integrated formulation development, manufacture and clinical testing service for oral dosage forms.
Quotient Clinical, a division of drug development services provider Quotient Bioresearch, has published a white paper demonstrating the capabilities of its RapidFACT integrated formulation development, manufacture and clinical testing service for oral dosage forms.
A conventional drug product optimisation process involves iterative rounds of screening multiple formulation prototypes in preclinical species to identify a limited number of lead systems to progress into human clinical PK studies. This process is time consuming and expensive. Quotient says RapidFACT can reduce this timeline by up to two-thirds and significantly reduces associated costs.
RapidFACT exploits Quotient's Translational Pharmaceutics platform, which integrates formulation development, GMP drug product manufacture and clinical testing facilities to allow products to be manufactured and investigated in a clinical study in 24 hours.
Candidate formulations can be rapidly screened, selected and validated on the basis of human clinical data. This significantly improves the precision by which an optimal drug product that matches the desired target product profile can be identified, the company says.